Abstract: The present invention is related to systems of administration of enzymes or other proteins, preferably for use in enzyme replacement therapy (ERT), in particular for the treatment of Lysosomal diseases. In particular, the invention encompasses the preparation of a composition based on nanostructured lipid systems and its use in the manufacture of a therapeutic product.

Abstract: The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: a) at least 0.4% w/v of bilastine, of formula or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; b) at least one ?-cyclodextrin; and c) at least one pharmaceutically acceptable water-soluble gelling agent; and wherein the pH is comprised between 4 and 9. and its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis.

Abstract: Aqueous pharmaceutical system for the administration of drugs to the nails. The invention relates to a topical preparation for treating diseases of the toenails and/or hands nails, based on a thermosensitive aqueous gel that at room temperature behaves as a dissolution and after application of nails, forming a hydrated layer, film or hydrogel from which release the active ingredients. The composition of the gel contains mostly water, a gel-forming polymer sensitive to changes in temperature, solubilizing agents and enhancers of absorption and/or penetration of the drug in nails.